Log in to your Inderes Free account to see all free content on this page.

BioArctic

319.40 SEK

+4.24 %

Less than 1K followers

BIOA B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+4.24 %

+13.18 %

+1.46 %

+59.54 %

+60.10 %

+75.59 %

+7.47 %

+232.02 %

+1,001.38 %

BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.

Market cap

28.31B SEK

Turnover

100.34M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

18.2.

2026

Annual report '25

20.5.

2026

Interim report Q1'26

28.5.

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Press release22 hours ago

BioArctic: New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment

Regulatory press release11/28/2025, 5:30 PM

Number of shares and votes in BioArctic AB (publ) as of November 28, 2025

Regulatory press release11/28/2025, 5:30 AM

BioArctic: New drug application for subcutaneous formulation of Leqembi[®] submitted in Japan

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/25/2025, 12:37 PM

BioArctic: Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose

Press release11/18/2025, 11:30 PM

BioArctic: New data on lecanemab to be presented at CTAD conference

Press release11/18/2025, 10:32 AM

Redeye: BioArctic (Q3 Review) - Stable progress

Press release11/13/2025, 11:30 PM

BioArctic: Leqembi® approved for IV maintenance treatment in the United Kingdom

BioArctic, Audiocast, Q3'25

Webcast11/13/2025, 8:30 AM

BioArctic, Audiocast, Q3'25

Regulatory press release11/13/2025, 7:00 AM

BioArctic: Interim Report for the period July - September 2025

Press release11/10/2025, 2:00 PM

Modular Finance IR Consensus: BioArctic – Consensus estimates Q3 2025

Press release11/4/2025, 9:00 AM

Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET

Regulatory press release10/30/2025, 10:00 AM

BioArctic: Sales of Leqembi® totaled 18 billion yen in the third quarter 2025

Press release10/26/2025, 11:35 PM

BioArctic: Health Canada Grants Authorization for Leqembi® (lecanemab)

Regulatory press release10/17/2025, 1:00 PM

BioArctic presents Nomination Committee

Press release10/14/2025, 7:05 AM

BioArctic: First patient treated with Leqembi® (lecanemab) in the Nordics

Press release10/14/2025, 5:00 AM

BioArctic: Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025

Press release10/6/2025, 8:35 PM

BioArctic: Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

Regulatory press release9/29/2025, 6:15 AM

BioArctic: Leqembi® approved for IV maintenance treatment in China

Regulatory press release9/24/2025, 6:40 AM

BioArctic: Leqembi® approved for the treatment of early Alzheimer's disease in Australia

Press release9/9/2025, 11:13 AM

Redeye: BioArctic - Strong momentum, fair price

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.